TTI-10001

TTI-10001 is a **non-cyclic dinucleotide small molecule STING agonist** developed by **Trillium Therapeutics** for cancer immunotherapy. It is designed to activate **stimulator of interferon genes** signaling to enhance innate immune sensing of tumor-derived cytosolic DNA and promote antitumor immunity. According to the provided context, the program was in **preclinical development** as of November 2019, with reported preclinical features including favorable potency, cell permeability, and tumor retention intended to address limitations of cyclic dinucleotide-derived STING agonists; in mouse studies, intratumoral or intravenous administration was reportedly well tolerated and induced complete regressions in injected and distal tumors with evidence of durable immunity. Trillium later discontinued internal discovery research activities and indicated the STING program was available for licensing while the company focused on other clinical assets.